A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies-Reference-Cited by-同舟云学术

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

Published:2015-01-29 Issue:10 Volume:121 Page:1645-1653
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Deeken John F.¹,Wang Hongkun²,Subramaniam Deepa²,He Aiwu Ruth²,Hwang Jimmy³,Marshall John L.²,Urso Christina E.²,Wang Yiru²,Ramos Corinne⁴,Steadman Kenneth²,Pishvaian Michael J.²

Affiliation:

1. Inova Comprehensive Cancer and Research Institute; Falls Church Virginia

2. Lombardi Comprehensive Cancer Center; Georgetown University Medical Center; Washington District of Columbia

3. Levine Cancer Center, Carolinas HealthCare System; Charlotte North Carolina

4. Theranostics Health, Inc.; Rockville Maryland

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29224/fullpdf

Reference35 articles.

1. Acquired resistance to EGFR-targeted therapies in colorectal cancer;Emburgh;Mol Oncol,2014

2. Acquired resistance to TKIs in solid tumors: learning from lung cancer;Cambridge;Nat Rev Clin Oncol,2014

3. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells;Erjala;Clin Cancer Res,2006

4. Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines;Learn;J Surg Res,2006

5. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo;Rajput;Cancer Res,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo;Toxicology and Applied Pharmacology;2024-01

2. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

3. Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

4. Towards precision oncology with patient-derived xenografts;Nature Reviews Clinical Oncology;2022-09-23

5. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma;Frontiers in Oncology;2022-05-18